Solid Biosciences Inc. 8-K

What Happened

• Solid Biosciences Inc. announced on March 6, 2026 that it entered a Securities Purchase Agreement to sell securities in a private placement expected to close around March 9, 2026. The deal would raise gross proceeds of approximately $240.0 million (about $226.8 million net after placement agent fees).
• The offering consists of 14,973,257 common shares at $5.61 per share and, for investors choosing that option in lieu of shares, 27,807,482 pre‑funded warrants priced at $5.609 each. Lead placement agents include Leerink Partners LLC and Citigroup Global Markets Inc.; other investors named include Perceptive Advisors, Bain Capital Life Sciences, RA Capital, Invus, Vestal Point Capital, Janus Henderson and Deep Track Capital.
• The company also reported a preliminary, unaudited cash, cash equivalents and available‑for‑sale securities balance of approximately $187.9 million as of December 31, 2025, and estimates that the combined proceeds and existing cash should fund operations into the first half of 2028 under its current plan.

Key Details

• Private placement: ~14.97M new common shares at $5.61 and/or ~27.81M pre‑funded warrants at $5.609 each; expected gross proceeds ≈ $240.0M, net ≈ $226.8M.
• Pre‑funded warrants: $0.001 exercise price, exercisable immediately; exercise blocked if it would push a holder above elected ownership limits (4.99% or 9.99%, adjustable with notice up to 19.99%).
• Registration rights: Company will file a resale registration statement within 30 days after closing and use best efforts to have it declared effective; failure to timely file or get effectiveness can trigger liquidated‑damages payments (1% of the investor’s invested amount per 30‑day period, subject to caps).
• Cash/runway: Preliminary cash position ≈ $187.9M (12/31/2025); company expects combined cash and net proceeds to fund operations into H1 2028 but says it may still need additional funding to complete development of its product candidates.

Why It Matters

• Funding and runway: This transaction, if closed as planned, materially bolsters Solid Biosciences’ cash position and extends its operating runway into 2028, reducing short‑term financing pressure for investors and partners.
• Dilution and resale: The sale of shares and issuance of pre‑funded warrants will dilute existing shareholders; registration rights mean those new securities will be registered for resale relatively quickly, which can increase liquidity for new investors and supply of tradable shares.
• Risks remain: The cash figure for year‑end 2025 is preliminary and unaudited, and the private placement is subject to closing conditions. The company cautions it may still need additional funding to complete development programs, and the timing/amounts could change.